Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metronidazole in Rectal Adenocarcinoma Undergoing Neoadjuvant Therapy
NCT06569368Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2024
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of metronidazole in rectal adenocarcinoma, sponsored by University of Texas MD Anderson Cancer Center. Started Jul 2024; status: recruiting.
02
Drugs
metronidazole
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on NCT06569368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06569368.